Contact information

Clara Redondo

Quality Assurance Lead

I joined Oxford Cancer Trials as a Trial Administrator in March 2017. Prior to this I was a Postdoctoral Researcher developing inhibitors for specific kinases selected as targets for therapeutic interventions, at the Structural Genomics Consortium in Oxford.

My current role focuses on the set-up, activation and follow-up activities, amendment processing and team communications in a varied portfolio of Oncological and Haematological Trials. I was promoted to take the lead for Quality Assurance in the Unit in 2023.

Recent publications

Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.

Miranda F. et al, (2016), Cancer cell, 30, 273 - 289

Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed mice.

Martin DSD. et al, (2016), J Mol Endocrinol, 56, 261 - 271

Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.

Campos-Sandoval JA. et al, (2011), J Med Chem, 54, 4378 - 4387

More publications